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Background. Chronic inflammation and composition of the colon microbiota have been associated with colorectal cancer in
humans. The human commensal enterotoxigenic Bacteroides fragilis (ETBF) is linked to both inflammatory bowel disease and co-
lorectal cancer and, in our murine model, causes interleukin 17A (IL-17A)–dependent colon tumors. In these studies, we hypoth-
esized that persistent colonization by ETBF is required for tumorigenesis.
Methods. We established a method for clearing ETBF in mice, using the antibiotic cefoxitin. Multiple intestinal neoplasia mice
were colonized with ETBF for the experiment duration or were cleared of infection after 5 or 14 days. Gross tumors and/or micro-
adenomas were then evaluated. In parallel, IL-17A expression was evaluated in wild-type littermates.
Results. Cefoxitin treatment resulted in complete and durable clearance of ETBF colonization. We observed a stepwise increase
in median colon tumor numbers as the duration of ETBF colonization increased before cefoxitin treatment. ETBF eradication also
significantly decreased mucosal IL-17A expression.
Conclusions. The timing of ETBF clearance profoundly influences colon adenoma formation, defining a period during which
the colon is susceptible to IL-17A–dependent tumorigenesis in this murine model. This model system can be used to study the mi-
crobiota-dependent and molecular mechanisms contributing to IL-17A–dependent colon tumor initiation.
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The risk of colorectal cancer (CRC) increases with the duration
of colitis, the anatomic extent of disease, and the degree of in-
flammation. Patients with ulcerative colitis and Crohn’s disease
have an estimated 2–3-fold higher incidence of CRC than the
general population [1]. The microbiota, or the diverse popula-
tion of microbes (primarily bacteria) in the gut, plays a crucial
role in intestinal health, and, alternatively, dysbiosis, or the dis-
ruption of the microbiota, is suspected to contribute to the de-
velopment of CRC [2, 3].
A key player in dysbiosis and the development of CRC may
be the bacterial symbiont enterotoxigenic Bacteroides fragilis
(ETBF). ETBF is a molecular subset of Bacteroides fragilis dis-
tinguished by the secretion of a sole pathogenic factor, the B.
fragilis toxin (BFT) [4, 5]. Increased detection of ETBF has
been reported in patients with inflammatory bowel disease
and those with CRC [6–8].
Murine ETBF infection causes brief, acute colitis character-
ized by rapid and robust colonic activation of the signal trans-
ducer and activator of transcription 3 protein (Stat3), which
drives a T-helper type 17 (Th17) immune response and evolves
into chronic colitis [9, 10]. Further, ETBF colonization of mul-
tiple intestinal neoplasia (Min) mice induces numerous distal
colon adenomas. Min mice are heterozygous for the wild-
type gene encoding adenomatous polyposis coli (Apc), a
tumor suppressor gene mutated in the majority of human
CRC cases; however ApcMin-driven tumors in these mice de-
velop predominantly in the small bowel, with very few tumors
in the colon unless the mice are colonized with ETBF [9, 11].
Notably, ETBF colonization of germ-free mice results in rapid
death (within 1 day) due to overwhelming colitis, suggesting
that, in this model, the microbiota temper ETBF virulence to
enable persistent asymptomatic colonization of the mouse
colon [12].
Here we determined whether persistent colon colonization by
ETBF is essential for tumorigenesis in the MinApcΔ716 mouse.
B. fragilis is known to favor mucosal colonization, and tools
to selectively remove any B. fragilis strain from the complex mu-
cosal or luminal microbiota are not yet available. Thus, we used
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ETBF infection time courses to assess whether the acute colonic
response to ETBF is sufficient to drive tumorigenesis after ETBF
(and microbiota) clearance with the antibiotic cefoxitin. Fur-
ther, we assessed whether the cefoxitin-induced clearance of
ETBF would result in loss of the interleukin 17A (IL-17A) im-
mune response or whether the elevated IL-17A response would
persist and continue to drive disease. Patients with strong,
chronic Th17 type (ie, IL-17A–driven) intestinal inflammation
with CRC have a worse prognosis [13, 14]. Therefore, this model
could aid in developing therapies for these high-risk patients.
MATERIALS AND METHODS
Bacteriology
ETBF strain 86-5443-2-2 (a clindamycin-resistant isolate from
piglet; kindly provided by Lyle Myers, Montana State Universi-
ty) was grown anaerobically overnight at 37°C in brain heart in-
fusion (BHI) medium (BD Diagnostic Systems) supplemented
with 5 g/L yeast extract (Difco), 0.1 mg/L vitamin K (Sigma-
Aldrich), 0.5 mg/L hemin (Sigma-Aldrich), 50 mg/L L-cysteine,
and 6 g/L clindamycin (Sigma-Aldrich).
Antibiotic Minimum Inhibitory Concentrations (MICs) for ETBF
ETBF organisms in suspension were added to 2 mL of BHI such
that the bacteria were at a concentration of 5 × 105 colony-
forming units (CFU)/mL. Antibiotics (metronidazole, doxycy-
cline, or cefoxitin) were added to final concentrations of 0.5, 1,
2, 4, 8, 16, and 32 µg/mL. Metronidazole, doxycycline, or
cefoxitin were present during growth for 48 hours at 37°C in
an anaerobic chamber (AS-580 Anaerobe Chamber, Anaerobe
Systems). The MIC end point was defined as the lowest concen-
tration without visible growth.
Animals
MinApcΔ716 (kindly provided by Dr David Huso [Johns Hop-
kins]) and C57BL/6J (Jackson Laboratories) Helicobacter
species–free and specific-pathogen-free mice, kept in conven-
tional housing, were genotyped and inoculated with bacteria
as described previously [11, 12] Mice were inoculated with
approximately 108 CFU ETBF in phosphate-buffered saline
(PBS; approximately 0.1 mL) by oral gavage. As described in
“Results” section, ETBF-colonized mice were given antibiotics
in the drinking water (their sole water source) as follows: cefoxitin
(Apotex), 0.5 mg/mL in water; doxycycline (Hospira), 1 mg/mL
in water; and metronidazole (Hospira), 2 mg/mL in 2% grape
Kool-Aid (to mask the bitter taste; Dr T. Stappenbeck [Washing-
ton University, St. Louis, MO], personal communication); for
metronidazole experiments, control mice were also given the fla-
vored water. Antibiotics were given for 14 days unless otherwise
stated. A group of ETBF-infected mice were also treated by gavage
with metronidazole, 22.5 mg/kg once per day for 7 days. To limit
fecal matter as a source of reinfection, cages were changed when
starting antibiotic-containing water, 2 days after starting antibiot-
ic-containing water, and then at least weekly.
To prepare tissue specimens for colon polyp analysis, mice
were euthanized by CO2 asphyxiation, and colons and ceca
were removed, fixed, and stained as described previously [9].
Briefly, to count visible tumors, colons were opened longitu-
dinally and laid flat for fixation with 10% buffered formalin.
Colons were then stained with methylene blue for tumor visual-
ization and counted under a Leica ES2 dissecting scope. For
microadenoma counts, colons were flushed, swiss-rolled into cry-
omolds (Tissue Tek), and submerged in 10% buffered formalin
for 48 hours prior to histopathologic processing. Microadenoma
counts were averaged from two 5-µm sections obtained at 75-µm
intervals and stained with hematoxylin and eosin.
All mouse protocols were approved by the Johns Hopkins
University Animal Care and Use Committee in accordance
with the Association for Assessment and Accreditation of Lab-
oratory Animal Care International.
Fecal Analysis of Colonic ETBF Colonization
ETBF Colony-Forming Units (CFU) per Gram of Stool
Colonization was quantified by plating serial dilutions of stool
specimens suspended in PBS on BHI-clindamycin agar plates
and incubating them for 48 hours in anaerobic conditions at
37°C. Colonization was generally within the range of 108–1010
CFU/g stool at 3–5 days after inoculation. ETBF colonies are phe-
notypically recognizable as opaque and domed, compared with
other opportunistic colonies; however, putative ETBF colonies
were also spot checked for the presence of bft2, using standard
polymerase chain reaction (PCR) analysis (forward primer, 5′-
TCC CTC TTT GGC GTC GCC-3′; and reverse primer, 5′-
CGC TCG GGC AAC TAT-3′) as described previously [15].
Stool DNA Isolation
DNA was isolated from fecal pellets, using the Qiagen QIAamp
DNA Stool Mini Kit according to the manufacturer’s instructions.
Peptone Yeast Glucose With Bile (PYGB) Liquid Broth
Amplification
To ensure clearance of ETBF, stool bacteria were enriched using
Bacteroides species–selective PYGB liquid broth (Anaerobe Sys-
tems) and incubated anaerobically at 37°C for 48 hours followed
by PCR analysis for the bft gene (forward, 5′-GAA CCT AAA
ACG GTA TAT GT-3′; and reverse, 5′-GTT GTA GAC ATC
CCA CTG GC-3′).
Mucosal Colonization
To evaluate ETBF mucosal colonization, the most distal 2 cm of
the colon was washed twice in 1 mL of 0.016% DTT in saline to
remove loosely adherent bacteria. Tissue pieces were weighed,
homogenized, and serially diluted in PBS. Serial dilutions
were plated on BHI-clindamycin agar plates to detect ETBF col-
onies, and the number of CFU per gram of tissue was calculated.
TaqMan qPCR Analysis
Distal colon tissues for RNA isolation were snap frozen in
RNAlater (Ambion). RNA was extracted using the Qiagen
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Qiacube according to the manufacturer’s instructions. TaqMan
primers (Life Technologies) were used according to the manu-
facturer’s instructions. Fold-changes from values for sham con-
trols were calculated; threshold cycle values were normalized to
those for 18S.
Statistical Analysis
To compare measurements across experimental conditions, we
used the Mann–Whitney U test or Kruskal–Wallis test as indi-
cated for continuous variables and the Pearson χ2 test for the
categorical variable of tumor size distribution, using Prism 6,
version 6.04.
RESULTS
Antibiotic Susceptibility in Culture Does Not Translate to Fecal or
Mucosal Clearance in Mice Infected With ETBF
To assess the susceptibility of ETBF to antibiotics commonly
used to treat infections with Bacteroides species, we first estab-
lished the ETBF-specific MICs of cefoxitin, doxycycline, and
metronidazole to be 8 µg/mL, 8 µg/mL, and 2 µg/mL, respec-
tively, with concentrations of >16 µg/mL (for cefoxitin and
doxycycline) and >2 µg/mL (for metronidazole) indicative of
resistance to these antibiotics. Although ETBF was susceptible
to all 3 antibiotics in vitro, only peroral cefoxitin consistently
cleared ETBF when measured by fecal or mucosal colonization
(Figure 1A and 1B). In contrast, fecal and mucosal colonization
confirmed persistent ETBF colonization in doxycycline- and
metronidazole-treated mice (Figure 1A and 1B). Treatment of
ETBF infection with daily metronidazole for 1 week by gavage
also did not clear ETBF colonization (data not shown).
To ensure cefoxitin-induced ETBF clearance was complete
and durable, we amplified the Bacteroides species present in
the stool by using PYGB broth and performed PCR to detect
the presence of bft. PYGB broth amplification is 2–4 orders of
magnitude more sensitive for detecting ETBF colonization
than PCR analysis to detect bft in DNA isolated directly
from stool (Supplementary Figure 1). Unexpectedly, we
found that ETBF was undetectable after the first day of cefox-
itin treatment (Figure 1C). Consistent with ETBF clearance by
cefoxitin, cecal contraction, an indication of inflammation,
was reversed by 2 days after cefoxitin treatment of ETBF-
colonized mice (Supplementary Figure 2). Additional experi-
ments also revealed that cefoxitin-treated mice quickly
(within 72 hours) reassemble a microbiota (C. Craig and C,
Sears, unpublished observations). Further, ETBF was not de-
tectible at the latest time point assayed, 37 days after cefoxitin
removal. Thus, we used oral cefoxitin treatment to test the hy-
pothesis that ETBF clearance would diminish ETBF-induced
tumorigenesis.
Figure 1. Peroral cefoxitin clears enterotoxigenic Bacteroides fragilis (ETBF) colonization. Wild-type C57Bl/6 mice were colonized with ETBF (for 2 weeks) and then treated
for 14 days with cefoxitin (0.5 mg/mL), metronidazole (metro; 2 mg/mL), and doxycycline (doxy; 1 mg/mL) via drinking water. A and B, ETBF colonization was assessed by stool
plating (A) and mucosal adherence (B). C, Cefoxitin clearance of fecal ETBF, tested using polymerase chain reaction for detection of bft after enrichment with fecal Bacteroides-
selective peptone yeast glucose with bile liquid broth. Stool specimens from ETBF alone mice and mice from the first, second, and third days of cefoxitin treatment are shown.
Each lane represents an individual mouse. −, negative control (no template); +, positive control (ETBF DNA). Abbreviation: CFU, colony-forming units.
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Timing of ETBF Clearance Profoundly Influences Macroscopic Colon
Tumor Numbers
We next examined the impact of ETBF clearance by cefoxitin on
colon tumorigenesis in MinApcΔ716 mice (Figure 2A). Briefly,
ETBF colonization for either 5 or 14 days was followed by cefox-
itin treatment for 14 days (hereafter, the 5-day ETBF + cfx
group and the 2-week ETBF + cfx group, respectively), and
the 5-day ETBF + cfx and 2-week ETBF + cfx groups were com-
pared to parallel MinApcΔ716 mouse groups colonized with
ETBF and not given cefoxitin (3 independent experiments
were performed, with 17–23 mice/group). Cefoxitin treatment
decreased the number of colon tumors significantly (Figure 2B
and 2C). However, the timing of cefoxitin commencement sig-
nificantly influenced ETBF-driven colon tumor numbers, with
a stepwise increase in the median number of colon tumors that
paralleled the number of days of ETBF colonization (median
number of colon tumors, 2 in the 5-day ETBF + cfx group, 8
in the 2-week ETBF + cfx group, and 19 in the ETBF alone
group). The distribution of tumor sizes was also affected, imply-
ing that tumors that do form after cefoxitin treatment may grow
or progress more slowly (Figure 2D).
Cefoxitin Treatment Reduces the Number of Microadenomas in
ETBF-Colonized MinApcΔ716 Mice
Microadenomas are adenomas that are not grossly visible, are
not polyploid, and are characterized by dysplasia with pro-
nounced nuclear atypia and a loss of nuclear polarity (Figure 3A)
[16].Microadenoma formation precedes the formation of macro-
adenomas. Because cefoxitin treatment reduced the number of
macroadenomas formed, we sought evidence that cefoxitin
treatment changes the initiation of microadenomas or their pro-
gression to macroadenomas by counting the number of microa-
denomas present, using histopathologic analysis, at multiple time
points after ETBF inoculation (Figure 3).
Data for microadenoma counts at day 19 and 28 after inocu-
lation (pooled) are representative of the pattern that significantly
Figure 2. Reduction in adenoma formation in cefoxitin (cfx)–treated mice is dependent on duration of enterotoxigenic Bacteroides fragilis (ETBF) colonization. A, Experi-
mental time line. B, Representative photographs of colons from mice colonized with ETBF for 8 weeks without treatment (ETBF alone), mice colonized with ETBF for 2 weeks and
then treated with cfx for 2 weeks (2-wk ETBF + cfx), and mice colonized with ETBF for 5 days and then treated with cfx for 2 weeks (5-d ETBF + cfx). Total number of tumors for
the colon shown are in parentheses next to image. C, Total number of macroscopic colonic tumors for each mouse. The number of tumors in the ETBF alone group was
significantly higher than in the 2-wk ETBF + cfx group (*P = .0067) and the 5-d ETBF + cfx group (#P < .0001). The difference in tumor numbers between the 2-wk ETBF + cfx
group and the 5-d ETBF + cfx group was also significant (**P < .0001). D, Colon adenomas grouped according to size: ≤1 mm2, >1 to ≤2 mm2, and ≥2 mm2. The χ2 statistic is
54.58, and the P value is <.00001. For size assessment, the number of mice per group was as follows: ETBF alone group, 7; 2-wk ET + cfx group, 14; and 5-d ETBF + cfx group, 12.
Abbreviation: col, colonization.
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fewer microadenomas were detected in the cefoxitin groups,
compared with the ETBF alone group (Figure 3B). No microade-
nomas were observed in sham MinApcΔ716 mice harvested at the
same ages as the ETBF-infected group, supporting the critical
contribution of ETBF colonization to microadenoma initiation.
IL-17A Cytokine Expression in the Distal Colon Decreases Significantly
Only in Mice Treated With Cefoxitin After 5 Days of ETBF Colonization
Colonic tumor formation in ETBF-colonized MinApcΔ716 mice
is dependent on a Th17 immune response [9]. Thus, we exam-
ined the impact of ETBF clearance by cefoxitin on IL-17A ex-
pression in the most distal 2 cm of the colon at time points from
5 to 28 days after ETBF colonization for all 3 treatment groups
(Table 1). Here, we used C57Bl/6 wild-type mice (background
mouse of MinApcΔ716) to avoid confounding IL-17A expression
by the high levels of IL-17A detected in ETBF-induced colon
microadenomas or tumors (Housseau, Wu, DeStefano Shields,
Sears, unpublished data). In C57Bl/6 mice, IL-17A expression is
elevated by day 5 of ETBF colonization, reaching a peak at ap-
proximately 10 days after which colonic IL-17A expression de-
clines but remains significantly elevated, compared with that in
controls up to 1 year later [10]. In contrast, compared with wild-
type ETBF-colonized mice, IL-17A expression was significantly
decreased in the 5-day ETBF + cfx group 7, 10, and 14 days after
colonization. Mice in the 2-week ETBF + cfx group also had de-
creased IL-17A expression upon ETBF eradication but did not
differ significantly from time-matched ETBF only controls.
DISCUSSION
Previously we demonstrated that ETBF colonization induces
inflammation and IL-17A–dependent colon adenomas in
MinApcΔ716 mice [9]. Early acute inflammation may also play
an important role in disease progression, given that epigenetic
silencing complexes have been shown to be recruited to chro-
matin within 48 hours of ETBF inoculation [17]. However,
whether these early events are sufficient for tumor formation
and whether the continued presence of ETBF is essential for
colon tumor initiation and/or progression are unknown.
Our key finding is that median adenoma formation decreased
by almost 10-fold when ETBF was cleared within 5 days of col-
onization but only approximately 2-fold when cleared after 14
days of colonization by using this cefoxitin model. These results
suggests that key disease drivers occur within a small interval in
this model and that focusing on this interval may yield impor-
tant mechanisms for procarcinogenic inflammatory, epigenetic,
and genetic studies. Our results do not specifically discern
whether the colon tumorigenesis observed results from ETBF
colonization alone or requires interaction with other microbiota
species [18]. However, we note that ETBF is rapidly lethal in
germ-free mice [12], suggesting that, at least in our model,
the murine microbiota dampens ETBF pathogenicity. Addi-
tionally, Min mice colonized with normal, or conventional,
gut flora form very few if any tumors in the colon; thus,
ETBF acts as a driver for tumorigenesis. Treatment with the
Figure 3. A, Representative images of microadenomas after enterotoxigenic Bacteroides fragilis (ETBF) colonization. B, Microadenoma formation in the colons of MinApcΔ716+/−
mice in groups colonized with ETBF without treatment (ETBF alone) or with cefoxitin treatment; average microadenomas are counted for 2 hematoxylin-eosin–stained sections per
mouse. Analysis of the 3 groups was performed by the Kruskal–Wallis test (P = .0017). Pair-wise comparisons were performed by the Mann–Whitney U test for comparison of mice
in the ETBF alone group to mice colonized with ETBF for 2 weeks and then treated with cfx for 2 weeks (2-wk ETBF + cfx; *P = .0038); comparison of mice in the ETBF alone group to
mice colonized with ETBF for 5 days and then treated with cfx for 2 weeks (5-d ETBF + cfx; **P = .0009); and comparison of mice in the 5-d ETBF + cfx group to mice in the 2-wk
ETBF + cfx group (P = .4857).
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Table 1. Interleukin 17A Expression in the Distal Colon of Wild-Type C57Bl/6 Mice
Variable
Harvest Day
5 7 10 14 16 19 28
ETBF alone
Condition 5 d of ETBF col 7 d of ETBF col 10 d of ETBF col 14 d of ETBF col 16 d of ETBF col 19 d of ETBF col 28 d of ETBF col
IL-17A level 76.4 (37.3–230.2) 106.3 (52.7–295.9) 369.3 (211.1–560.3) 234.9 (57.4–369.4) 124.1 (83.6–178.2) 42.8 (20.0–97.4) 74.0 (21.1–151.0)
Mice, no. 6 6 4 6 5 5 4
5-d ETBF+cfx
Condition 5 d of ETBF col 5 d of ETBF col plus 2 d
of cfx
5 d of ETBF col plus 5 d
of cfx
5 d of ETBF col plus 9 d
of cfx
5 d of ETBF col plus 11 d
of cfx
5 d of ETBF col plus 14 d
of cfx
5 d of ETBF col, 14 d of cfx,
plus 8 d after cfx end
IL-17A level ND 25.9 (8.6–108.8) 25.6 (10.2–33.7) 7.3 (5.4–35.3) ND ND 43.0 (14.8–98.6)
Mice, no. . . . 6 5 5 . . . . . . 4
Pa .026 .0159 .0043 .4857
2-wk ETBF+cfx
Condition 5 d of ETBF col 7 d of ETBF col 10 d of ETBF col 14 d of ETBF col 2 wk of ETBF col plus 2 d
of cfx
2 wk of ETBF col plus 5 d
of cfx
2 wk of ETBF col plus 14 d
of cfx
IL-17A level ND ND ND ND 28.1 (17.5–133.1) 36.4 (33.5–58.7) 11.6 (4.0, 19.2)
Mice, no. . . . . . . . . . . . . 4 5 2
Pa .111 .9004 .1333
RNA isolated from the most distal centimeter of the colon was analyzed for IL-17A expression by TaqMan quantitative polymerase chain reaction at the times indicated. IL-17A expression was normalized to that of 18S, and changes are expressed as the fold-
change from median sham control values (range).
Abbreviations: col, colonization; ETBF, enterotoxigenic Bacteroides fragilis; ETBF alone, mice colonized with ETBF without treatment; ND, not done; 2-wk ETBF+cfx, mice colonized with ETBF for 2 weeks and then treated with cefoxitin for 2 weeks; 5-d
ETBF+cfx, mice colonized with ETBF for 5 days and then treated with cefoxitin for 2 weeks.
a By the Mann–Whitney U test, for comparison with the ETBF alone group at the specified harvest time.
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broad-spectrum antibiotic cefoxitin to eradicate ETBF also
changes the gut flora of the experimental mice. However,
given the very low tumor burden of this genetic background,
it is experimentally challenging to discern the contribution of
the microbiota to baseline tumorigenesis in this Min mouse
model. Additional data indicate that an in-frame bft deletion
mitigates ETBF pathogenicity (F. Housseau and S. Wu et al, un-
published data), confirming the importance of BFT to the col-
itic and tumorigenic potential of ETBF. However, tools to
induce time-dependent BFT neutralization or bft excision
would be helpful to examine with precision the selective contri-
bution of BFT (vs other microbiota members or molecules) to
the development of colitis and colon tumors.
Of note, although ETBF eradication by cefoxitin therapy
was accompanied by an abrupt reduction in colonic IL-17A
levels, expression did not decrease to the levels of sham con-
trols. We hypothesize that, in this IL-17A–dependent model,
clearance of ETBF blunts the IL-17A response. However,
colon adenoma formation in the 2-week ETBF + cfx group
suggests that, in many mice, tumorigenesis had progressed
and/or a procarcinogenic mucosal immune environment was
established such that ETBF clearance was not sufficient to
prevent either tumor initiation or its progression. Namely,
the majority of the 2-week ETBF + cfx mice exhibited tumor
numbers exceeding those of sham controls. Notably, we used
wild-type mice for our IL-17A studies, to avoid confounding
influences by the IL-17A–rich tumor microenvironment of
the Min mouse, with or without ETBF colonization [19]. Fur-
ther studies are warranted to define the immune, molecular,
and/or environmental signals initiated by ETBF colonization
that are required for altering IL-17A homeostasis in the
colon, as well as the accelerated colon adenoma initiation in
the ETBF model.
Treatment of or immunization against infectious agents (eg,
Helicobacter pylori, hepatitis B and C viruses, and human pap-
illomavirus) can have a dramatic effect on cancer development.
Courses of antibiotics to clear asymptomatic colonization by en-
teric bacteria are currently not advisable, particularly due to the
risks of development of antibiotic resistance, as well as disrup-
tion of the normal microbiota that can precipitate short-term
complications of antibiotic therapy, as occurs with Clostridium
difficile colitis [20]. In addition, there is rising concern that
microbiota disruptions result in long-term, disease-inducing
microbiota dysbiosis [21]. Further, bacteria proposed as initia-
tors/promoters of CRC (eg, ETBF, Fusobacterium nucleatum,
and Escherichia coli [pks]) are not routinely sought as patho-
gens in clinical medicine, and it is unclear whether detection
and clearance of chronic colonizing, putatively oncogenic,
bacteria will modify long-term risk for CRC. Our ETBF colon
tumorigenesis model is markedly accelerated (approximately
100-fold) as compared to our understanding of the protracted
time course for the development of human colon neoplasias.
Nonetheless, our results suggest that early interventions in in-
fection-related procarcinogenic colitis associated with induction
of mucosal IL-17A could blunt colon polyp/adenoma forma-
tion, a known precursor lesion of CRC.
Our work presented here is novel because we have established
an early, brief interval (5–14 days after ETBF colonization) in
which ETBF colonization induces the majority of the IL-17A–
dependent colon tumorigenesis burden in mice. ETBF-induced
inflammation is sufficient to produce microadenomas in 5 days,
yet very early clearance of ETBF allows for the regression of dis-
ease. Thus, this model provides an opportunity to define the
molecular sequence of events crucial to IL-17A–dependent
colon adenoma initiation and progression, with the potential
to define testable biomarkers for early detection of carcinogenic
potential in the colon.
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